UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                   May 8, 2006
                Date of Report (Date of earliest event reported)

                    KIWA BIO-TECH PRODUCTS GROUP CORPORATION
             (Exact name of registrant as specified in its charter)

         Delaware                       000-33167                84-0448400
(State or other jurisdiction           (Commission            (I.R.S. Employer
      of incorporation)                File Number)          Identification No.)

       415 West Foothill Blvd, Suite 206, Claremont, California 91711-2766
       -------------------------------------------------------------------
                    (Address of principal executive offices)

                                 (909) 626-2358
                                 --------------
              (Registrant's telephone number, including area code)

                                       N/A
                                       ---
          (Former Name or Former Address, if changed since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 1.01     Entry into Material Definitive Agreements.

On May 8, 2006 the Company  entered into a Technology  Transfer  Agreement  with
Jinan  Kelongboao  Bio-Tech Co. Ltd.  ("JKB").  Pursuant to the  Agreement,  JKB
agrees to  transfer  its AF-01  Anti-viral  Aerosol  technology  for  veterinary
medicines to the  Company.  The AF-01  technology,  which can be used to deliver
animal vaccines by aerosol spray,  is recognized by a technological  achievement
appraisal  certificate  issued  by  the  government  of  China.  JKB  agrees  to
facilitate  transfer of the technology by providing  consulting  services to the
Company and to cooperate in the development of an animal vaccine product for the
market.  Pursuant to the  agreement  the Company  will pay JKB a transfer fee of
Renminbi  (RMB)10  million  (approximately  US$1.247  million),  of which  RMB 6
million will be paid in cash and RMB 4 million  will be paid in stock.  The cash
portion will be paid in instalments,  the first RMB 3 million instalment due May
23, 2006 and three other RMB 1 million  instalments  due upon the achievement of
certain milestones, the last milestone being the issuance by the PRC Ministry of
Agriculture of a new medicine certificate in respect of the technology.  The RMB
4 million  stock  payment  will be due 90 days  after the  AF-01  technology  is
approved by the  appropriate  PRC department for use as a livestock  disinfector
for  preventing  bird flu.  The original  agreement  is in Mandarin.  An English
translation of the agreement is included as an exhibit to this report.

On May 10, 2006 the Company entered into an Acquisition Framework Agreement with
Beijing Huasheng Medicine Co. ("BSM"). The agreement expresses the mutual intent
of the  parties to enter into an  acquisition  transaction  in which the Company
will acquire 60% of the equity of BSM. In exchange for the 60% equity stake, the
Company  will  contribute  its  recently   acquired  AF-01  Anti-viral   Aerosol
technology  as well as a cash  payment  that is  subject to  negotiation  but is
expected  by the  Company  to be  approximately  RMB 12  million  (approximately
US$1.487  million).  The  acquisition is subject to the parties  entering into a
definitive agreement relating to the transaction, obtaining requisite regulatory
approvals,  and to the Company's  raising funds to pay the purchase price. It is
anticipated  that the closing of the transaction will occur in the third quarter
of 2006. The original  agreement is in Mandarin.  An English  translation of the
agreement is included as an exhibit to this report.

Item 9.01  Financial Statements and Exhibits

(d) Exhibits

     Exhibit No.    Exhibit Title
     10.01          Technology Transfer Agreement between the Company and Jinan
                    Kelongboao Bio-Tech Co. Ltd., dated May 8, 2006
     10.02          Acquisition Framework Agreement between the Company and
                    Beijing Huasheng Medicine Co., dated May 10, 2006


                                       2
<PAGE>

                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.


/S/ LI WEI                          May 12, 2006, Chairman of Board of Directors
------------------                                and Chief Executive Officer
Wei Li


                                       3
{"company-data": {"conformed-name": "KIWA BIO-TECH PRODUCTS GROUP CORP", "cik": "0001159275", "assigned-sic": "8731", "irs-number": "870448400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-33167", "film-number": "06839040"}, "business-address": {"street1": "17700 CASTLETON STREET", "street2": "SUITE 589", "city": "CITY OF INDUSTRY", "state": "CA", "zip": "91748", "phone": "(626) 964-3232"}, "mail-address": {"street1": "17700 CASTLETON STREET", "street2": "SUITE 589", "city": "CITY OF INDUSTRY", "state": "CA", "zip": "91748"}, "former-company": {"former-conformed-name": "TINTIC GOLD MINING  CO", "date-changed": "20010918"}}
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                   May 8, 2006
                Date of Report (Date of earliest event reported)

                    KIWA BIO-TECH PRODUCTS GROUP CORPORATION
             (Exact name of registrant as specified in its charter)

         Delaware                       000-33167                84-0448400
(State or other jurisdiction           (Commission            (I.R.S. Employer
      of incorporation)                File Number)          Identification No.)

       415 West Foothill Blvd, Suite 206, Claremont, California 91711-2766
       -------------------------------------------------------------------
                    (Address of principal executive offices)

                                 (909) 626-2358
                                 --------------
              (Registrant's telephone number, including area code)

                                       N/A
                                       ---
          (Former Name or Former Address, if changed since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01     Entry into Material Definitive Agreements.

On May 8, 2006 the Company  entered into a Technology  Transfer  Agreement  with
Jinan  Kelongboao  Bio-Tech Co. Ltd.  ("JKB").  Pursuant to the  Agreement,  JKB
agrees to  transfer  its AF-01  Anti-viral  Aerosol  technology  for  veterinary
medicines to the  Company.  The AF-01  technology,  which can be used to deliver
animal vaccines by aerosol spray,  is recognized by a technological  achievement
appraisal  certificate  issued  by  the  government  of  China.  JKB  agrees  to
facilitate  transfer of the technology by providing  consulting  services to the
Company and to cooperate in the development of an animal vaccine product for the
market.  Pursuant to the  agreement  the Company  will pay JKB a transfer fee of
Renminbi  (RMB)10  million  (approximately  US$1.247  million),  of which  RMB 6
million will be paid in cash and RMB 4 million  will be paid in stock.  The cash
portion will be paid in instalments,  the first RMB 3 million instalment due May
23, 2006 and three other RMB 1 million  instalments  due upon the achievement of
certain milestones, the last milestone being the issuance by the PRC Ministry of
Agriculture of a new medicine certificate in respect of the technology.  The RMB
4 million  stock  payment  will be due 90 days  after the  AF-01  technology  is
approved by the  appropriate  PRC department for use as a livestock  disinfector
for  preventing  bird flu.  The original  agreement  is in Mandarin.  An English
translation of the agreement is included as an exhibit to this report.

On May 10, 2006 the Company entered into an Acquisition Framework Agreement with
Beijing Huasheng Medicine Co. ("BSM"). The agreement expresses the mutual intent
of the  parties to enter into an  acquisition  transaction  in which the Company
will acquire 60% of the equity of BSM. In exchange for the 60% equity stake, the
Company  will  contribute  its  recently   acquired  AF-01  Anti-viral   Aerosol
technology  as well as a cash  payment  that is  subject to  negotiation  but is
expected  by the  Company  to be  approximately  RMB 12  million  (approximately
US$1.487  million).  The  acquisition is subject to the parties  entering into a
definitive agreement relating to the transaction, obtaining requisite regulatory
approvals,  and to the Company's  raising funds to pay the purchase price. It is
anticipated  that the closing of the transaction will occur in the third quarter
of 2006. The original  agreement is in Mandarin.  An English  translation of the
agreement is included as an exhibit to this report.

Item 9.01  Financial Statements and Exhibits

(d) Exhibits

     Exhibit No.    Exhibit Title
     10.01          Technology Transfer Agreement between the Company and Jinan
                    Kelongboao Bio-Tech Co. Ltd., dated May 8, 2006
     10.02          Acquisition Framework Agreement between the Company and
                    Beijing Huasheng Medicine Co., dated May 10, 2006

                                       2
SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

/S/ LI WEI                          May 12, 2006, Chairman of Board of Directors
------------------                                and Chief Executive Officer
Wei Li

                                       3